Last C$0.65 CAD
Change Today +0.03 / 4.84%
Volume 172.4K
As of 3:59 PM 08/23/13 All times are local (Market data is delayed by at least 15 minutes).

resverlogix corp (RVX) Snapshot

Open
C$0.63
Previous Close
C$0.62
Day High
C$0.67
Day Low
C$0.62
52 Week High
05/21/13 - C$3.83
52 Week Low
06/27/13 - C$0.15
Market Cap
48.7M
Average Volume 10 Days
330.9K
EPS TTM
C$-0.59
Shares Outstanding
75.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
RVX:CN Advanced Stock Chart

Related News

No related news articles were found.

resverlogix corp (RVX) Related News

No Related News Found

resverlogix corp (RVX) Key Developments

Resverlogix Corp. Auditor Raises 'Going Concern' Doubt

Resverlogix Corp. filed its Annual on Jul 26, 2013 for the period ending Apr 30, 2013. In this report its auditor, KPMG LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Resverlogix Mulls Acquisitions

Resverlogix Corp. (TSX:RVX) is seeking acquisition opportunities. Donald McCaffrey, President, Chief Executive Officer and Co-Founder of Resverlogix said at the conference call, "M&A acquisition is still an option. However, that would depend on more successful data coming out of the rest of the ASSURE trial."

Resverlogix Corp. - Special Call

Resverlogix Corp. - Special Call


1 RVX $18.46
+0.22 (1.21%)

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RVX:CN C$0.65 CAD +0.03

RVX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RVX.

Industry Analysis

RVX

Industry Average

Valuation RVX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs


    We are currently experiencing technical difficulties. Please try again later.
Simply Hired

Sponsored Links


otc, otcbb, pinksheet, RVX, ob Resverlogix Corp


Resverlogix Corp Stock

Resverlogix Corp., a biotechnology company, engages in the development of novel therapies for cardiovascular disease (CVD), cancer, and fibrotic diseases. The company’s development programs include NexVas Plaque Regression, a technology platform, which is in two Phase 2b clinical trials with RVX-208 for the development of drugs that increase ApoA-I to reduce the risk of CVD; and NexVas Autoimmune, a preclinical technology for the development of drugs that target molecular markers of inflammation, such as Multiple Sclerosis and Rheumatoid Arthritis. Its development programs also include NexVas Alzheimer’s Disease, a neurovascular focused program for the development of drugs that enhance ApoA-I and RCT markers for stabilization and the potential transport of Beta Amyloid Plaque; and ReVas, a research stage technology for the development of therapeutics to be used with medical devices for the treatment of cardiovascular diseases. The company is headquartered in Calgary, Canada.
No related news found for this RVX.


All quotes are delayed. All information is provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Quote Stock nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing Quote Stock, you agree to our disclaimer.
@2013 www.quote-stocks.com is a part of The Stock Space financial network – (646) 402-6200. ContactUs Disclamier Privacy Policy